DOCSLIB.ORG

REVIEW Nucleoside Analogues: Mechanisms of Drug Resistance and Reversal Strategies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
REVIEW Nucleoside Analogues: Mechanisms of Drug Resistance and Reversal Strategies Leukemia (2001) 15, 875–890 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu REVIEW Nucleoside analogues: mechanisms of drug resistance and reversal strategies CM Galmarini1, JR Mackey2 and C Dumontet1,3 1Unite´ INSERM 453, Laboratoire de Cytologie Analytique, Faculte´ de Me´de´cine Rockefeller, Lyon, France; 2Medical and Experimental Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada; and 3Service d’He´matologie, Centre Hospitalier Lyon Sud, France Nucleoside analogues (NA) are essential components of AML ter drugs have mostly been used in the treatment of low-grade induction therapy (cytosine arabinoside), effective treatments hematological malignancies.8,9 of lymphoproliferative disorders (fludarabine, cladribine) and are also used in the treatment of some solid tumors The importance of NA chemotherapeutic agents has (gemcitabine). These important compounds share some gen- recently increased as a result of the introduction of new com- eral common characteristics, namely in terms of requiring pounds into clinical use and the expansion of indications into transport by specific membrane transporters, metabolism and the field of solid tumors. During the same period, there has interaction with intracellular targets. However, these com- been rapid progress in the understanding of mechanisms of pounds differ in regard to the types of transporters that most drug resistance to NA. In this review, we highlight the current efficiently transport a given compound, and their preferential interaction with certain targets which may explain why some knowledge concerning the cellular mechanisms of resistance compounds are more effective against rapidly proliferating to NA and possible strategies that may be used to overcome tumors and others on neoplasia with a more protracted evol- such resistance. ution. In this review, we analyze the available data concerning mechanisms of action of and resistance to NA, with particular emphasis on recent advances in the characterization of nucleo- Normal nucleoside transport and phosphorylation side transporters and on the potential role of activating or inac- tivating enzymes in the induction of clinical resistance to these compounds. We performed an extensive search of published Because physiologic nucleosides are generally hydrophilic in vitro and clinical data in which the levels of expression of and do not readily permeate the plasma membrane, their nucleoside-activating or inactivating enzymes have been corre- cellular uptake occurs primarily via nucleoside-specific mem- lated with tumor response or patient outcome. Strategies aim- brane transport carriers (NT). Of the seven distinct NT activi- ing to increase the intracellular concentrations of active com- ties observed in human cells, only four have been defined pounds are presented. Leukemia (2001) 15, 875–890. 9 in molecular terms. These are classified into two categories: Keywords: nucleoside analogues; nucleoside transporters; 5 - 10,11 nucleotidase; drug resistance equilibrative (ENT) or concentrative (CNT). Human equil- ibrative NTs (hENTs) are found in virtually all studied cell types and have broad permeant selectivity, accepting both Introduction purine and pyrimidine nucleosides as substrates. The two cloned hENTs differ in their sensitivity to inhibition by nano- Nucleoside analogues (NA) constitute an important class of molar concentrations of nitrobenzylmercaptopurine ribonu- antimetabolites used in the treatment of hematological malig- cleoside (NBMPR): hENT1 has es activity (equilibrative and 1 NBMPR-sensitive) while hENT2 possesses ei (equilibrative and nancies and, more recently, in solid tumors. These thera- 12–14 peutic compounds mimic physiological nucleosides in terms NBMPR-insensitive) nucleoside transport activity. The of uptake and metabolism and are incorporated into newly human concentrative nucleoside transporters (hCNT) are synthesized DNA resulting in synthesis inhibition and chain inwardly-directed transporters that are capable of transporting nucleosides against a concentration gradient by utilizing the termination. Some of these drugs also inhibit key enzymes 15–17 involved in the generation of the purine and pyrimidine transmembrane sodium concentration gradient. The nucleotides and RNA synthesis, and directly activate the hCNT1 protein has greater affinity for pyrimidine nucleosides but also transports adenosine, while the hCNT2 protein trans- caspase cascade. All of these effects may lead to cell death. 18 The NA family includes various pyrimidine and purine ana- ports purine nucleosides and uridine. In all cases, human logues. Among the pyrimidine analogues cytosine arabinoside NTs accept only dephosphorylated compounds. (ara-C, cytarabine) is extensively used in the treatment of Deoxyribonucleotide triphosphate (dNTPs) pools present acute leukemia, while gemcitabine has more recently demon- within cells come from two sources, the de novo pathway strated activity in pancreatic, breast and lung cancer.2–4 The which is specifically activated in replicating cells, and the sal- vage pathway, which is the main source of nucleotides in two first purine analogues to have been described were the 19,20 thiopurines 6 mercaptopurine (6-MP) and 6-thioguanine (6- quiescent cells. The key step in the de novo pathway is TG). These compounds could more appropriately be desig- the conversion of ribonucleoside diphosphates into deoxyri- nated as ‘nucleobases’. Other new purine analogues are 2- bonucleoside diphosphates by ribonucleotide reductase (RR). chlorodeoxyadenosine (2-CdA) and fludarabine.5–7 These lat- Replicating hematopoietic cells are heavily dependent on the de novo pathway. Conversely in resting cells the salvage path- way, which recycles bases and nucleosides derived from DNA or RNA catabolism, is the unique provider of dNTPs. These Correspondence: CM Galmarini, Laboratoire de Cytologie Analytique, Faculte´ de Me´decine Rockefeller, 8 Avenue Rockefeller, 69373, Lyon compounds are first phosphorylated by nucleoside kinases Cedex 08, France; Fax: 33 4 78 95 35 05 such as deoxycytidine kinase (dCK), thymidine kinase 1 and Received 21 September 2000; accepted 1 February 2001 2, or deoxyguanosine kinase (dGK). This initial phosphoryl- Nucleoside analogues: mechanisms of drug resistance and reversal strategies CM Galmarini et al 876 Table 1 Human nucleoside transporters (NT) mediating uptake of nucleoside analogues NT ara-Ca Gemcitabine Fludarabine 2-CdA Ref. hENT1 ++++ ++++ +++ ++++ 16, 96, 242, 95, 243 hENT2 ND ++ ++ ++ 11, 54, 81 hCNT1 + ++++ − − 17, 54, 81 hCNT2 ND −−− 18, 81 ND, not determined. aDegree of transport: (+), low transported; (++), moderate transported; (+++/++++), highly transported; (−), not transported. ation step constitutes the key step in the salvage pathway that to ‘self-potentiate’ their own cytotoxic effects. However each concludes with the formation of triphosphate or deoxytri- of these compounds also possesses specific properties in terms phosphate derivatives. There are thus two dNTP pools: one of drug–target interactions which may explain their differences derived from the de novo pathway that is predominantly in activity in various diseases. In particular the cytotoxic directed into replicating DNA and a second derived from effects of the purine analogues fludarabine and 2-CdA on salvage synthesis used for DNA repair.21,22 quiescent cells may be explained by interaction with targets involving DNA repair rather than replication, and direct or indirect effects on mitochondria. Mechanisms of action of nucleoside analogues and drug metabolism Ara-C All of the NA share common characteristics including active transport by membrane transporters (Table 1), activation by Ara-C (1-β-D-arabinofuranosylcytosine, cytosine arabinoside, kinases such as dCK allowing retention of the monophosphate cytarabine) is an structural analogue of deoxycytidine (dCyd) residues in the cell and the formation of the active triphos- (Figure 2) used for the treatment of acute leukemias and lym- phates metabolites, and dephosphorylation by 59-nucleotidase phomas. Ara-C differs from dCyd by the presence of a (59-NU) (Figure 1). Moreover, most of them have the ability hydroxyl group in the β-configuration at the 29-position of the sugar moiety. Intracellular penetration of ara-C depends on plasma ara-C concentrations.23–26 Standard-dose ara-C (SD ara-C; 100–200 mg/m2) achieves steady-state plasma levels of 0.5–1 µM.27,28 At these concentrations the expression of the hENT1 protein is the rate-limiting factor in ara-C uptake. In the presence of plasma concentrations greater than 50 µM, such as those reached with high-dose ara-C (HD ara-C; 2–3 g/m2), simple inward diffusion rates exceed those of pump- mediated transport.29 Once inside the cell, ara-C is phosphorylated by dCK and pyrimidine kinases to the active 59-triphosphate derivative ara- CTP.30,31 The catabolism of ara-C results from rapid deamin- ation by cytidine deaminase (CDD) to the non-toxic metab- olite arabinoside uridine while ara-CMP is dephosphorylated by the action of cytoplasmic 59-nucleotidase (59-NU).32 Ara- C cytotoxicity is believed to result from a combination of DNA polymerase inhibition and from incorporation of ara-CTP into Figure 1 Representation of the metabolism and drug target interac- tions of deoxynucleoside analogues in proliferating cells (NA). NA enters cells via specific nucleoside transporters. Once inside the cell, NA are phosphorylated by deoxycytidine kinase (DCK), NMPK and
Load more

Recommended publications
  • Nucleoside Phosphate-Conjugates Come of Age: Catalytic Transformation, Polymerase Recognition and Antiviral Properties.# Elisabetta Groaz* and Piet Herdewijn
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Lirias Send Orders for Reprints to [email protected] Current Medicinal Chemistry, Year, Volume 1 Nucleoside Phosphate-Conjugates Come of Age: Catalytic Transformation, Polymerase Recognition and Antiviral Properties.# Elisabetta Groaz* and Piet Herdewijn Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium Abstract: Over the past few decades, different types of nucleoside phosphate-conjugates have been under extensive investigation due to their favorable molecular lability with interesting catalytic hydrolysis mechanisms, recognition as polymerase substrates, and especially for their development as antiviral/anticancer protide therapeutics. The antiviral conjugates such as nucleoside phosphoesters and phosphoramidates that were discovered and developed in the initial years have been well reviewed by the pioneers in the field. In the present review, we will discuss the basic chemical and biological principles behind consideration of some representative structural classes. We will also summarize the chemical and biological properties of some of the more recent analogues that were synthesized and evaluated in our laboratory and by others. This includes new principles for their application as direct substrates of polymerases, nucleobase-dependent catalytic and antiviral activity, and a plausible ‘prodrug of a prodrug’ strategy for tissue/organ-specific targeted drug delivery. Keywords: Prodrug – Delivery – Stability – Polymerase - Phosphoramidates INTRODUCTION profile of these molecules through the “tuning” of the nature of the existing ligands and the pursuit of new protecting The ability of unnatural nucleoside-based therapeutics to moieties relying on chemical rather than enzymatic induce inhibition of uncontrolled cell proliferation or viral dependant activation mechanisms.
    [Show full text]
  • SYN-40585 SYNRIBO Digital PI, Pil and IFU 5/2021 V3.Indd
    SYN-40585 CONTRAINDICATIONS HIGHLIGHTS OF PRESCRIBING INFORMATION None. These highlights do not include all the information needed to use SYNRIBO safely and WARNINGS AND PRECAUTIONS effectively. See full prescribing information for SYNRIBO. • Myelosuppression: Severe and fatal thrombocytopenia, neutropenia and anemia. Monitor SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use hematologic parameters frequently (2.3, 5.1). Initial U.S. Approval: 2012 • Bleeding: Severe thrombocytopenia and increased risk of hemorrhage. Fatal cerebral hemorrhage and severe, non-fatal gastrointestinal hemorrhage (5.1, 5.2). INDICATIONS AND USAGE Hyperglycemia: Glucose intolerance and hyperglycemia including hyperosmolar non-ketotic SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated • hyperglycemia (5.3). phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the tyrosine kinase inhibitors (TKI) (1). • potential risk to a fetus and to use an effective method of contraception (5.4, 8.1, 8.3). DOSAGE AND ADMINISTRATION ADVERSE REACTIONS Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • Most common adverse reactions (frequency ≥ 20%): thrombocytopenia, anemia, neutropenia, 14 consecutive days of a 28-day cycle (2.1). diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, and lymphopenia Maintenance Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • (6.1). 7 consecutive days of a 28-day cycle (2.2). • Dose modifications are needed for toxicity (2.3). To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • Depression of Thymidylate Synthetase Activity in Response to Cytosine Arabinoside1
    [CANCER RESEARCH 32, 1160-1169, June 1972] Depression of Thymidylate Synthetase Activity in Response To Cytosine Arabinoside1 DeWayne Roberts and Ellen V. Loehr St. Jude Children's Research Hospital, Memphis, Tennessee 38101 ¡D.R., E. V. L.J and Department of Pharmacology, University of Tennessee Medical Units, Memphis, Tennessee 38101 [D. R.J SUMMARY Cytosine arabinoside induces remission of acute granulocytic leukemia (11). After the administration of Depression of thymidylate synthetase activity by cytosine cytosine arabinoside to patients, changes in the enzyme arabinoside in CCRF-CEM cells was correlated with a blocking activity pattern of leukemic leukocytes occur (32). After drug of precursor incorporation into RNA and with cell lysis. With administration, a decrease in thymidylate synthetase activity is increasing concentrations of cytosine arabinoside in the observed as early as 1 hr and persists for 24 hr in some culture media, a proportional decrease of uridine patients. A concentration-dependent decrease in thymidylate incorporation into RNA and decrease in thymidylate synthetase activity also follows the addition of cytosine synthetase activity occurred and was accompanied by lysis of arabinoside to CCRF-CEM cultures (33). the cells. These effects continued to develop with drug Methotrexate elevates thymidylate synthetase activity in concentrations in excess of that required to block thymidine leukocytes from patients with acute leukemia (32), in rat liver incorporation into DNA. The addition of deoxycytidine at and transplantable tumors (27), and in cells of LI210 or concentrations that failed to reverse inhibition by cytosine CCRF-CEM cultures (32, 33). The simultaneous addition of arabinoside of thymidine incorporation into DNA reversed the cytosine arabinoside and methotrexate to CCRF-CEM cultures drug effects on uridine incorporation, thymidylate synthetase modulated the effect of each drug on thymidylate synthetase activity, and cell lysis.
    [Show full text]
  • Nucleotide Degradation
    Nucleotide Degradation Nucleotide Degradation The Digestion Pathway • Ingestion of food always includes nucleic acids. • As you know from BI 421, the low pH of the stomach does not affect the polymer. • In the duodenum, zymogens are converted to nucleases and the nucleotides are converted to nucleosides by non-specific phosphatases or nucleotidases. nucleases • Only the non-ionic nucleosides are taken & phospho- diesterases up in the villi of the small intestine. Duodenum Non-specific phosphatases • In the cell, the first step is the release of nucleosides) the ribose sugar, most effectively done by a non-specific nucleoside phosphorylase to give ribose 1-phosphate (Rib1P) and the free bases. • Most ingested nucleic acids are degraded to Rib1P, purines, and pyrimidines. 1 Nucleotide Degradation: Overview Fate of Nucleic Acids: Once broken down to the nitrogenous bases they are either: Nucleotides 1. Salvaged for recycling into new nucleic acids (most cells; from internal, Pi not ingested, nucleic Nucleosides acids). Purine Nucleoside Pi aD-Rib 1-P (or Rib) 2. Oxidized (primarily in the Phosphorylase & intestine and liver) by first aD-dRib 1-P (or dRib) converting to nucleosides, Bases then to –Uric Acid (purines) –Acetyl-CoA & Purine & Pyrimidine Oxidation succinyl-CoA Salvage Pathway (pyrimidines) The Salvage Pathways are in competition with the de novo biosynthetic pathways, and are both ANABOLISM Nucleotide Degradation Catabolism of Purines Nucleotides: Nucleosides: Bases: 1. Dephosphorylation (via 5’-nucleotidase) 2. Deamination and hydrolysis of ribose lead to production of xanthine. 3. Hypoxanthine and xanthine are then oxidized into uric acid by xanthine oxidase. Spiders and other arachnids lack xanthine oxidase.
    [Show full text]
  • Modifications of Nucleic Acid Precursors That Inhibit Plant Virus Multiplication
    Molecular Plant Pathology Modifications of Nucleic Acid Precursors That Inhibit Plant Virus Multiplication William 0. Dawson and Carol Boyd Department of Plant Pathology, University of California, Riverside 92521. This work was supported in part by U.S. Department of Agriculture Grant 84-CTC-1-1402. Accepted for publication 4 April 1986. ABSTRACT Dawson, W. 0., and Boyd, C. 1987. Modifications of nucleic acid precursors that inhibit plant virus multiplication. Phytopathology 77:477-480. The relationship between chemical modifications of normal nucleic acid highest proportion of antiviral activity were modification of the sugar base or nucleoside precursors and ability to inhibit multiplication of moiety (five of 13 chemicals were inhibitory) and addition of abnormal side tobacco mosaic virus or cowpea chlorotic mottle virus in disks from groups (three of seven chemicals were inhibitory). Eight new inhibitors of mechanically inoculated leaves was tested with 131 analogues. Chemicals virus multiplication were identified: 6-aminocytosine; 6-ethyl- tested were selected from 10 general classes of modifications to determine mercaptopurine; isopentenyladenosine; 2-thiopyrimidine; 2,4-dithio- the types of modifications of normal nucleic acid precursors that have pyrimidine; melamine; 5'-iodo-5'-deoxyadenosine; and 5'- greater probabilities of inhibiting virus multiplication. No inhibitory methyl-5'-deoxythioadenosine. chemicals were found in several classes. Classes of modifications with the Additionalkey words: antivirals, chemotherapy, control, virus diseases. The ability to control virus diseases of plants with chemicals different taxonomic groups, tobacco mosaic virus (TMV) in would be a valuable addition to existing control strategies. This tobacco and cowpea chlorotic mottle virus (CCMV) in cowpea. could be particularly useful in in vitro culture procedures to Chemicals were chosen to be tested based on two different criteria.
    [Show full text]
  • 2'-Deoxyguanosine Toxicity for B and Mature T Lymphoid Cell Lines Is Mediated by Guanine Ribonucleotide Accumulation
    2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. Y Sidi, B S Mitchell J Clin Invest. 1984;74(5):1640-1648. https://doi.org/10.1172/JCI111580. Research Article Inherited deficiency of the enzyme purine nucleoside phosphorylase (PNP) results in selective and severe T lymphocyte depletion which is mediated by its substrate, 2'-deoxyguanosine. This observation provides a rationale for the use of PNP inhibitors as selective T cell immunosuppressive agents. We have studied the relative effects of the PNP inhibitor 8- aminoguanosine on the metabolism and growth of lymphoid cell lines of T and B cell origin. We have found that 2'- deoxyguanosine toxicity for T lymphoblasts is markedly potentiated by 8-aminoguanosine and is mediated by the accumulation of deoxyguanosine triphosphate. In contrast, the growth of T4+ mature T cell lines and B lymphoblast cell lines is inhibited by somewhat higher concentrations of 2'-deoxyguanosine (ID50 20 and 18 microM, respectively) in the presence of 8-aminoguanosine without an increase in deoxyguanosine triphosphate levels. Cytotoxicity correlates instead with a three- to fivefold increase in guanosine triphosphate (GTP) levels after 24 h. Accumulation of GTP and growth inhibition also result from exposure to guanosine, but not to guanine at equimolar concentrations. B lymphoblasts which are deficient in the purine salvage enzyme hypoxanthine guanine phosphoribosyltransferase are completely resistant to 2'-deoxyguanosine or guanosine concentrations up to 800 microM and do not demonstrate an increase in GTP levels. Growth inhibition and GTP accumulation are prevented by hypoxanthine or adenine, but not by 2'-deoxycytidine.
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • Burkitt Lymphoma
    NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Burkitt Lymphoma (Part 1 of 3) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Induction Therapy—Low Risk Combination Regimens1,a Note: All recommendations are Category 2A unless otherwise indicated. REGIMEN DOSING CODOX-M
    [Show full text]
  • The Biochemistry of Gout: a USMLE Step 1 Study Aid
    The Biochemistry of Gout: A USMLE Step 1 Study Aid BMS 6204 May 26, 2005 Compiled by: Todd Kerensky Elizabeth Ballard Brendan Prendergast Eric Ritchie 1 Introduction Gout is a systemic disease caused by excess uric acid as the result of deficient purine metabolism. Clinically, gout is marked by peripheral arthritis and painful inflammation in joints resulting from deposition of uric acid in joint synovia as monosodium urate crystals. Although gout is the most common crystal-induced arthritis, a condition known as pseudogout can commonly be mistaken for gout in the clinic. Pseudogout results from deposition of calcium pyrophosphatase (CPP) crystals in synovial spaces, but causes nearly identical clinical presentation. Clinical findings Crystal-induced arthritis such as gout and pseudogout differ from other types of arthritis in their clinical presentations. The primary feature differentiating gout from other types of arthritis is the spontaneity and abruptness of onset of inflammation. Additionally, the inflammation from gout and pseudogout are commonly found in a single joint. Gout and pseudogout typically present with Podagra, a painful inflammation of the metatarsal- phalangeal joint of the great toe. However, gout can also present with spontaneous edema and painful inflammation of any other joint, but most commonly the ankle, wrist, or knee. As an exception, a spontaneous painful inflammation in the glenohumeral joint is usually the result of pseudogout. It is important to recognize the clinical differences between gout, pseudogout and other types of arthritis because the treatments differ markedly (Kaplan 2005). Pathophysiology and Treatment of Gout Although gout affects peripheral joints in clinical presentation, it is important to recognize that it is a systemic disorder caused by either overproduction or underexcretion of uric acid.
    [Show full text]
  • Deoxyribonucleic Acid Synthesis I. Effect of in Vivo Cyclophosphamide
    ICANCER RESEARCH 26 Part 1, 1466-1472,July 1966] Deoxyribonucleic Acid Synthesis I. Effect of in Vivo Cyclophosphamide Treatment on the in Vitro Activity of the Deoxyribonucleic Acid Synthetase System of Sensitive and Resistant Plasmacytomas1 ARTHUR J. TOMISEK, MARTHA BRUCE IRICK, AND PAULA WEDELES ALLAN Kettering'-Meyer Laboratory,2 Southern Research Institute, Birmingham, Alabama Summary term DNA-synthetase. In addition to this measurement of over-all DNA synthetase activity, we used the same experiments We have shown that the in vivo treatment of Fortner plasma- to determine the time course of radioactivity distribution among cytomas with Cyclophosphamide can lead to strong inhibitions of both deoxyribonucleic acid nucleotidyl transferase and thymi- the soluble components of the synthetase reaction mixtures. Our data show that the observed decreases in enzyme activity dylatc kinase activities in the soluble cell fractions. However, in are among the possible consequences of growth inhibition in the allowing only 2 hr for the inhibitor to act, the effect observed on tumor. the transferase was an unexplained stimulation rather than an inhibition. We have also provided some evidence that the inhibition of Materials and Methods growth precedes the inhibition of deoxyribonucleic acid nucleo ENZYME PREPARATION.Fortner hamster plasmacytoma tidyl transferase activity. ("sensitive") (3) and ite cyclophosphamide-resistant subline (12) were used for bilateral s.c. implantation into groups of 6-12 Introduction Golden Syrian hamsters, the animals in each experiment being uniform with respect to commercial subline, sex, and approxi Previous studies in this laboratory have shown that several mate age. On the 12th-14th postimplant day the animals were alkylating agents inhibited the in vivo synthesis of DNA by divided into 2 subgroups, to receive daily i.p.
    [Show full text]
  • On-Demand Synthesis of Phosphoramidites
    ARTICLE https://doi.org/10.1038/s41467-021-22945-z OPEN On-demand synthesis of phosphoramidites Alexander F. Sandahl1, Thuy J. D. Nguyen1, Rikke A. Hansen1, Martin B. Johansen 1, Troels Skrydstrup 1,2 & ✉ Kurt V. Gothelf 1,2 Automated chemical synthesis of oligonucleotides is of fundamental importance for the production of primers for the polymerase chain reaction (PCR), for oligonucleotide-based drugs, and for numerous other medical and biotechnological applications. The highly opti- mised automised chemical oligonucleotide synthesis relies upon phosphoramidites as the 1234567890():,; phosphate precursors and one of the drawbacks of this technology is the poor bench stability of phosphoramidites. Here, we report on the development of an on-demand flow synthesis of phosphoramidites from their corresponding alcohols, which is accomplished with short reaction times, near-quantitative yields and without the need of purification before being submitted directly to automated oligonucleotide synthesis. Sterically hindered as well as redox unstable phosphoramidites are synthesised using this methodology and the sub- sequent couplings are near-quantitative for all substrates. The vision for this technology is direct integration into DNA synthesisers thereby omitting manual synthesis and storage of phosphoramidites. 1 Interdisciplinary Nanoscience Center, iNANO, Aarhus University, Aarhus C, Denmark. 2 Department of Chemistry, Aarhus University, Aarhus C, Denmark. ✉ email: [email protected] NATURE COMMUNICATIONS | (2021) 12:2760 | https://doi.org/10.1038/s41467-021-22945-z | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22945-z ynthetic oligonucleotides are essential for a range of dif- includetheuseofmechanochemistry11 or the use of P(V) chemistry Sferent areas and millions of oligonucleotides are synthesized to form the internucleosidic P–Obond12,13.
    [Show full text]
  • Design and Evaluation of 5•²-O-Dicarboxylic And
    University of Rhode Island DigitalCommons@URI Open Access Master's Theses 2014 DESIGN AND EVALUATION OF 5′-O-DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES Bhanu Priya Pemmaraju Venkata University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Pemmaraju Venkata, Bhanu Priya, "DESIGN AND EVALUATION OF 5′-O-DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES" (2014). Open Access Master's Theses. Paper 474. https://digitalcommons.uri.edu/theses/474 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. DESIGN AND EVALUATION OF 5′-O- DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES BY BHANU PRIYA, PEMMARAJU VENKATA A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE MASTER’S DEGREE IN BIOMEDICAL AND PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2014 MASTER OF SCIENCE THESIS OF BHANU PRIYA, PEMMARAJU VENKATA APPROVED: Thesis Committee: Major Professor Keykavous Parang Roberta King Stephen Kogut Geoffrey D. Bothun Nasser H. Zawia DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2014 ABSTRACT 2′,3′-Dideoxynucleoside (ddNs) analogs are the most widely used anti-HIV drugs in the market. Even though these drugs display very potent activities, they have a number of limitations when are used as therapeutic agents. The primary problem associated with ddNs is significant toxicity, such as neuropathy and bone marrow suppression.
    [Show full text]